The market is growing…

Nearly 12 million adults have been diagnosed with COPD in the U.S.

Asthma affects nearly 334 million people worldwide.

Air quality is on the decline.

The adoption of oxygen therapy is increasing and we saw a need for change. Our device leverages the latest in connected sensor technologies to deliver supplemental oxygen therapy. This next-gen tool uses wireless biometric data to automatically adjust the oxygen flow rates to optimal levels. This helps maintain saturation during activities such as walking, climbing stairs and even light exercise. Not only does this improve the activities of daily life, it optimizes oxygen use and reduces range anxiety allowing people to better plan their daily activities.

Something to help these millions of people that assists with controlled flow, efficient dosing, faster response rates with improved durability and reliability. We wanted oxygen therapy to feel as natural as possible and take the guesswork out of the process. t

Innovative Solution for Automated Supplemental Oxygen Control

Our device, MoblO₂, is for people with advanced lung disease who have been prescribed supplemental and long-term oxygen therapy (LTOT). It is designed to provide reliable, continuous monitoring and flow variability of the supplemental oxygen supply to assure stable oxygen saturation levels both efficiently and effectively.

To us, it is about restoring hope

This product is not currently available for sale in the United States.

We strive to restore a person’s hope and spirit for both the patient and caregiver by providing a smart technology device that takes the fear and anxiety out of supplemental oxygen management. Not only does MoblO2 ^TM provide convenience and comfort to the user, clinicians and researchers get best-in-class data through our cloud-based management system.